Asciminib Roll-over Study
This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment...
KRT-232 and TKI Study in Chronic Myeloid Leukemia
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to ...
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real w...
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP). T...
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have...
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib fro...
Top Cities for Chronic Myeloid Leukemia Clinical Trials
Chronic Myeloid Leukemia clinical trials are recruiting across 28 cities. Here are the cities with the most active studies:
About Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a type of cancer that starts in blood-forming cells of the bone marrow, characterized by the Philadelphia chromosome and BCR-ABL fusion gene. It was one of the first cancers treated successfully with targeted therapy. Tyrosine kinase inhibitors like imatinib have transformed CML into a manageable chronic condition.
Clinical trials are advancing new treatments for chronic myeloid leukemia. Currently, 6 studies are recruiting a combined 751 participants across the United States. Research is being conducted by 5 organizations including Novartis Pharmaceuticals, Kartos Therapeutics, Inc., Baylor College of Medicine and 2 others.
2026 Chronic Myeloid Leukemia Research Landscape
As of March 2026, the chronic myeloid leukemia clinical trial landscape includes 6 actively recruiting studies across 28 cities in the United States. These studies are collectively seeking 751 participants, with an average enrollment target of 125 per study.
Research is being led by 5 different organizations, including Novartis Pharmaceuticals, Kartos Therapeutics, Inc., Baylor College of Medicine, Augusta University, Medical College of Wisconsin.
Geographically, chronic myeloid leukemia trials are most concentrated in Houston, Texas (6 trials); New York, New York (4 trials); Milwaukee, Wisconsin (3 trials); Salt Lake City, Utah (3 trials); Augusta, Georgia (2 trials) and 7 other cities.
Featured Chronic Myeloid Leukemia Studies
Highlighted recruiting studies for chronic myeloid leukemia, selected by enrollment size and research scope.
Asciminib Roll-over Study
This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
KRT-232 and TKI Study in Chronic Myeloid Leukemia
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML...
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.
Frequently Asked Questions About Chronic Myeloid Leukemia Clinical Trials
Are there chronic myeloid leukemia clinical trials near me?
Yes, there are 6 chronic myeloid leukemia clinical trials currently recruiting across 28+ cities in the United States, including Houston, Texas; New York, New York; Milwaukee, Wisconsin. Browse the studies above to find one at a location convenient for you.
How do I join a chronic myeloid leukemia clinical trial?
To join a chronic myeloid leukemia clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are chronic myeloid leukemia clinical trials free?
Yes, participation in chronic myeloid leukemia clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of chronic myeloid leukemia treatments are being studied?
Current chronic myeloid leukemia clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 5 research organizations.
Is it safe to participate in chronic myeloid leukemia clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov